Zimmer Biomet — Aug 7, 2025 release

Page 4 of 24   Financial Guidance The Company is updating its full-year 2025 financial guidance to tighten full-year 2025 reported, constant currency and organic constant currency 1 revenue guidance and increase adjusted 2 earnings per share financial guidance: Projected Year Ending December 31, 2025     Previous Guidance Updated Guidance 2025 Reported Revenue Change 5.7% - 8.2% 6.7%- 7.7% Foreign Currency Exchange Impact 0.0% - 0.5% 0.5% 2025 Constant Currency Revenue Change 5.7% - 7.7% 6.2% - 7.2% 2025 Organic Constant Currency Revenue Change (1) 3.0% - 5.0% 3.5% - 4.5% Adjusted Diluted EPS (2) $7.90 - $8.10 $8.10 - $8.30   (1) Excludes the projected impact of the Paragon 28 acquisition. Reconciliation of this measure to the most directly comparable GAAP financial measure is included in this press release. (2) These measures are non-GAAP financial measures for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. Conference Call The Company will conduct its second quarter investor conference call today, August 7, 2025, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly trans